Lung Cancer Drug Cuts Tumor Growth by 65% in New Trial

Patients with advanced lung cancer just got their best news in years.

A new drug combination developed by Kelun-Biotech and licensed to Merck slashed the risk of tumor progression by 65% in a Phase 3 clinical trial, according to results presented Thursday at a major cancer research conference. The treatment, called sacituzumab tirumotecan, combines an antibody-drug conjugate with immunotherapy to attack cancer cells on two fronts.

The study focused on patients with non-small cell lung cancer, the most common form of the disease. All participants had advanced cancer but hadn't yet received treatment, making this a crucial first-line therapy option.

What makes this breakthrough special is the combination itself. Doctors have long hoped to pair antibody-drug conjugates, which deliver chemotherapy directly to cancer cells, with PD-1 immunotherapy drugs that help the immune system fight tumors. This is the first time that combination has succeeded in this patient population.

Early survival data also looks promising, though researchers need more time to confirm those results. The study took place in China, where lung cancer remains a leading cause of death.

The Ripple Effect

This success could reshape treatment for millions. Lung cancer affects over 2 million people worldwide each year, and non-small cell lung cancer accounts for about 85% of all cases.

The combination approach offers something particularly valuable: options. When one treatment pathway opens, it often reveals others, as researchers learn which mechanisms work well together.

For patients diagnosed today, the expanding toolkit of effective treatments means better odds and more hope. Each new successful trial brings science closer to turning deadly cancers into manageable chronic conditions.

The drug now moves toward regulatory approval processes, bringing it closer to patients who need it most. While the therapy was tested in China, Merck's involvement suggests broader availability could follow.

For families touched by lung cancer, news like this transforms the conversation from "if" to "when" better treatments arrive.